CN101389648A - 肽胃泌酸调节素衍生物 - Google Patents
肽胃泌酸调节素衍生物 Download PDFInfo
- Publication number
- CN101389648A CN101389648A CNA2007800061855A CN200780006185A CN101389648A CN 101389648 A CN101389648 A CN 101389648A CN A2007800061855 A CNA2007800061855 A CN A2007800061855A CN 200780006185 A CN200780006185 A CN 200780006185A CN 101389648 A CN101389648 A CN 101389648A
- Authority
- CN
- China
- Prior art keywords
- cys
- mpeg
- mod
- res
- cholest
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
SEQIDNO | 肽 | 序列 |
1 | OXM1 | HGQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAA-COOH |
2 | OXM2 | HGQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC2-COOH |
3 | OXM3 | HGQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC3-COOH |
4 | OXM-NH2 | HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
5 | Ac-OXM-NH2 | Ac-HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
6 | Ac-OXM | Ac-HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-COOH |
7 | OXM4 | HαQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-COOH |
8 | OXM5 | HVQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-COOH |
9 | OXM6 | HaQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-COOH |
10 | OXM7 | HsQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-COOH |
11 | OXM8 | HSEGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-COOH |
12 | OXM9 | HSDGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-COOH |
13 | OXM10 | HSLGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-COOH |
14 | OXM11 | HSnGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-COOH |
15 | OXM12 | HGEGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-COOH |
16 | OXM13 | FSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-COOH |
17 | OXM14 | Pyr-HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
18 | OXM15 | HSPGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-COOH |
19 | OXM16 | H1SQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
20 | OXM17 | Me-HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
21 | OXM18 | H2SQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
22 | OXM19 | Me2-HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
23 | OXM20 | Bz-HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
24 | OXM21 | Bzl-HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
25 | OXM23 | HAEGTFTSDVSSYLEGQAAKEFIAWLMNTKRNRNNIA-CONH2 |
26 | OXM24 | HSQGTFTSDYAKYLDARRAQDFVQWLMNTKRNRNNIA-CONH2 |
27 | OXM25 | HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNI-CONH2 |
28 | OXM26 | HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNN-CONH2 |
29 | OXM27 | HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRN-CONH2 |
30 | OXM28 | HαQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
31 | OXM29 | HαQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC-CONH2 |
32 | OXM30 | HαQGTFTSDYSKYLDSRRAQDFVQWLMCTKRNRNNIA-CONH2 |
33 | OXM31 | HsQGTFTSDYSKYLDSRRAQDFVQWLmNTKRNRNNIA-COOH |
34 | OXM32 | HsQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
35 | OXM33-36前体 | HsQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC-CONH2 |
36 | OXM33 | HsQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC1-CONH2 |
37 | OXM34 | HsQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC2-CONH2 |
38 | OXM35 | HsQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC3-CONH2 |
39 | OXM36 | HsQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC4-CONH2 |
40 | OXM37 | HAQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
41 | OXM38 | HRQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
42 | OXM39 | HNQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
43 | OXM40 | HDQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
44 | OXM41 | HEQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
45 | OXM42 | HQQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
46 | OXM43 | HHQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
47 | OXM44 | HIQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
48 | OXM45 | HLQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
49 | OXM46 | HKQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
50 | OXM47 | HMQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
51 | OXM48 | HFQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNrA-CONH2 |
52 | OXM49 | HPQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
53 | OXM50 | HTQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
54 | OXM51 | HWQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
55 | OXM52 | HYQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
56 | OXM53 | HsEGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-CONH2 |
57 | OXM54 | HsQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC5-CONH2 |
58 | OXM55-59前体 | HsQGTFTSDYSKYLDSRRACDFVQWLMNTKRNRNNIA-CONH2 |
59 | OXM55 | HsQGTFTSDYSKYLDSRRAC5DFVQWLMNTKRNRNNIA-CONH2 |
60 | OXM56 | HsQGTFTSDYSKYLDSRRAC1DFVQWLMNTKRNRNNIA-CONH2 |
61 | OXM57 | HsQGTFTSDYSKYLDSRRAC2DFVQWLMNTKRNRNNIA-CONH2 |
62 | OXM58 | HsQGTFTSDYSKYLDSRRAC3DFVQWLMNTKRNRNNIA-CONH2 |
63 | OXM59 | HsQGTFTSDYSKYLDSRRAC4DFVQWLMNTKRNRNNIA-CONH2 |
64 | OXM60 | HsQGTFTSDYSKYLDSRRAQDFVQWLnNTKRNRNNIA-CONH2 |
65 | OXM61 | HsQGTFTSDYSKYLDSRRAQDFVQWLMC5TKRNRNNIA-CONH2 |
66 | OXM62 | HsQGTFTSDYSKYLDSRRAQDFVQWLMC1TKRNRNNIA-CONH2 |
67 | OXM63 | HsQGTFTSDYSKYLDSRRAQDFVQWLMC2TKRNRNNIA-CONH2 |
68 | OXM64 | HsQGTFTSDYSKYLDSRRAQDFVQWLMC3TKRNRNNIA-CONH2 |
69 | OXM65 | HsQGTFTSDYSKYLDSRRAQDFVQWLMC4TKRNRNNIA-CONH2 |
70 | OXM66 | HαQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC5-CONH2 |
71 | OXM67 | HαQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC1-CONH2 |
72 | OXM68 | HαQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC2-CONH2 |
73 | OXM69 | HαQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC3-CONH2 |
74 | OXM70 | HαQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC4-CONH2 |
75 | OXM71 | HsEGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC-CONH2 |
76 | OXM72 | HsEGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC5-CONH2 |
77 | OXM73 | HsEGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC1-CONH2 |
78 | OXM74 | HsEGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC2-CONH2 |
79 | OXM75 | HsEGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC3-CONH2 |
80 | OXM76 | HsEGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC4-CONH2 |
81 | OXM77 | HsQGTFTSDYSKYLDSRRAQCFVQWLMNTKRNRNNIA-CONH2 |
82 | OXM78 | HsQGTFTSDYSKYLDSRRAQC5FVQWLMNTKRNRNNIA-CONH2 |
83 | OXM79 | HsQGTFTSDYSKYLDSRRAQC1FVQWLMNTKRNRNNIA-CONH2 |
84 | OXM80 | HsQGTFTSDYSKYLDSRRAQC2FVQWLMNTKRNRNNIA-CONH2 |
85 | OXM81 | HsQGTFTSDYSKYLDSRRAQC3FVQWLMNTKRNRNNIA-CONH2 |
86 | OXM82 | HsQGTFTSDYSKYLDSRRAQC4FVQWLMNTKRNRNNIA-CONH2 |
87 | OXM83 | HsQGTFTSDYSKYLDSRRAQDFVCWLMNTKRNRNNIA-CONH2 |
88 | OXM84 | HsQGTFTSDYSKYLDSRRAQDFVC5WLMNTKRNRNNrA-CONH2 |
89 | OXM85 | HsQGTFTSDYSKYLDSRRAQDFVC1WLMNTKRNRNNIA-CONH2 |
90 | OXM86 | HsQGTFTSDYSKYLDSRRAQDFVC2WLMNTKRNRNNIA-CONH2 |
91 | OXM87 | HsQGTFTSDYSKYLDSRRAQDFVC3WLMNTKRNRNNIA-CONH2 |
92 | OXM88 | HsQGTFTSDYSKXLDSRRAQDFVC4WLMNTKRNRNNIA-CONH2 |
93 | OXM89 | HsQGTFTSDYSKYLDSRRAQDFVQWLVNTKRNRNNIA-CONH2 |
94 | OXM90 | HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNR-CONH2 |
95 | OXM91 | HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRN-CONH2 |
96 | OXM92 | HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKR-CONH2 |
97 | OXM93 | HSQGTFTSDYSKYLDSRRAQDFVQWLMNTK-CONH2 |
98 | OXM94 | HαQGTFTSDYSKYLDSRRAQDFVQWLmNTKRNRNNIAC-CONH2 |
99 | OXM95 | HsDGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC5-CONH2 |
100 | OXM96 | HαEGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC5-CONH2 |
101 | OXM97 | HαDGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAC5-CONH2 |
102 | OXM98 | HαQGTFTSDYSKYLDSRRAQDFVQWLmNTKRNRNNIAC5-CONH2 |
103 | OXM99 | HαQGTFTSDYSKYLDSRRAQDFVQWLmNTKRNRNNIAC3-CONH2 |
104 | OXM100 | HαQGTFTSDYSKYLDSRRAQDFVQWLmNTKRNRNNIAC6-CONH2 |
105 | OXM101 | HαQGTFTSDYSKYLDSRRAQDFVQWLmNTKRNRNNIAC4-CONH2 |
106 | OXM102 | HαQGTFTSDYSKYLDSRRAC5DFVQWLMNTKRNRNNIA-CONH2 |
107 | OXM103 | HαQGTFTSDYSKYLDSRRAC3DFVQWLMNTKRNRNNIA-CONH2 |
108 | OXM104 | HαQGTFTSDYSKYLDSRRAQC5FVQWLMNTKRNRNNIA-CONH2 |
109 | OXM105 | HαQGTFTSDYSKYLDSRRAQC3FVQWLMNTKRNRNNIA-CONH2 |
110 | OXM106 | HαQGTFTSDYSKYLDSRRAQDFVC5WLmNTKRNRNNIA-CONH2 |
111 | OXM107 | HαQGTFTSDYSKYLDSRRAQDFVC3WLmNTKRNRNNIA-CONH2 |
112 | OXM108 | HαQGTFTSDYSKYLDSRRAQDFVQWLMC5TKRNRNNIA-CONH2 |
113 | OXM109 | HαQGTFTSDYSKYLDSRRAQDFVQWLMC3TKRNRNNIA-CONH2 |
114 | OXM110 | HsQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAK(棕榈酰基)-CONH2 |
115 | OXM111 | H2αQGTFTSDYSKYLDSRRAQDFVQWLmNTKRNRNNIAC-CONH2 |
116 | OXM112 | H2αQGTFTSDYSKYLDSRRAQDFVQWLmNTKRNRNNIAC5-CONH2 |
117 | OXM113 | H2αQGTFTSDYSKYLDSRRAQDFVQWLmNTKRNRNNIAC3-CONH2 |
118 | OXM114 | H2αQGTFTSDYSKYLDSRRAQDFVQWLmNTKRNRNNIAC4-CONH2 |
119 | OXM116 | HαDGTFTSDYSKYLDSRRAQDFVQWLmNTKRNRNNIAC-CONH2 |
120 | OXM117/145/146 | HαDGTFTSDYSKYLDSRRAQDFVQWLmNTKRNRNNIAC3-CONH2 |
121 | OXM118 | HαDGTFTSDYSKYLDSRRAQDFVQWLmNTKRNRNNIAC4-CONH2 |
122 | OXM119 | HαQGTFTSDYCKYLDSRRAQDFVQWLmNTKRNRNNIA-CONH2 |
123 | OXM120 | HαQGTFTSDYC5KYLDSRRAQDFVQWLmNTKRNRNNIA-CONH2 |
124 | OXM121 | HαQGTFTSDYC3KYLDSRRAQDFVQWLmNTKRNRNNIA-CONH2 |
125 | OXM122 | HαQGTFTSDYSCYLDSRRAQDFVQWLmNTKRNRNNIA-CONH2 |
126 | OXM123 | HαQGTFTSDYSC5YLDSRRAQDFVQWLmNTKRNRNNIA-CONH2 |
127 | OXM124 | HαQGTFTSDYSC3YLDSRRAQDFVQWLmNTKRNRNNIA-CONH2 |
128 | OXM125 | HαDGTFTSDYSKYLDSRRAC3DFVQWLmNTKRNRNNIA-CONH2 |
129 | OXM126 | HαQGTFTSDYSKYLDSRRAQDCVQWLmNTKRNRNNIA-CONH2 |
130 | OXM127 | HαQGTFTSDYSKYLDSRRAQDC4VQWLmNTKRNRNNIA-CONH2 |
131 | OXM128 | H2αDGTFTSDYSKYLDSRRACDFVQWLmNTKRNRNNIA-CONH2 |
132 | OXM129 | H2αDGTFTSDYSKYLDSRRAC3DFVQWLmNTKRNRNNIA-CONH2 |
133 | OXM130 | HαQGTFTSDYSKYLDSRRAQDFVQWLMNTK-CONH2 |
134 | OXM131 | HαDGTFTSDYSKYLDSRRAQDFVQWLMNTK-CONH2 |
135 | OXM132 | HαQGTFTSDYSKYLDSRRACDFVQWLmNTKRNRNNIA-CONH2 |
136 | OXM133 | HαQGTFTSDYSKYLDSRRAC5DFVQWLmNTKRNRNNIA-CONH2 |
137 | OXM134 | HαQGTFTSDYSKYLDSRRAC3DFVQWLmNTKRNRNNIA-CONH2 |
138 | OXM135 | HαQGTFTSDYSKYLDSRRACDFVQWLmNTK-CONH2 |
139 | OXM136 | HαQGTFTSDYSKYLDSRRAC3DFVQWLmNTK-CONH2 |
140 | OXM137 | HαDGTFTSDYSKYLDSRRACDFVQWLmNTK-CONH2 |
141 | OXM138 | HαDGTFTSDYSKYLDSRRAC3DFVQWLmNTK-CONH2 |
142 | OXM139 | HαDGTFTSDYSKYLDSRRAQDFVQWLmNTKRNRNNIAC8-CONH2 |
143 | OXM141 | HαDGTFTSDYSKYLDSRRAC3DFVQWLmNTKRNRNNIAC4-CONH2 |
144 | OXM142 | HαQGTFTSDYSKYLDSRRAC3DFVQWLmNTKRNRNNIAC4-CONH2 |
145 | OXM143 | HαQGTFTSDYSKYLDSRRAC8DFVQWLmNTK-CONH2 |
146 | OXM144 | HαDGTFTSDYSKYLDSRRAC8DFVQWLmNTK-CONH2 |
147 | OXM147 | HαQGTFTSDYSKYLDSRRACDFVQWLMNTK-CONH2 |
148 | OXM148 | HαQGTFTSDYSKYLDSRRAC8DFVQWLMNTK-CONH2 |
149 | OXM149 | HαDGTFTSDYSKYLDSRRACDFVQWLmNTk-CONH2 |
150 | OXM150 | HαDGTFTSDYSKYLDSRRAC8DFVQWLmNTk-CONH2 |
151 | OXM151 | HαDGTFTSDYSKYLDSEAAQDFVQWLmNTKRNRNNIAC-CONH2 |
152 | OXM152 | HαDGTFTSDYSKYLDS-TtdsEC-CONH2 |
153 | OXM153 | HαDGTFTSDYSKYLDSEAAQDFVQWLmNTKRNRNNIAC8-CONH2 |
154 | OXM154 | HαDGTFTSDYSKYLDSEAAQDFVQWLmNTKRNRNNIAC3-CONH2 |
155 | OXM155 | HαDGTFTSDYSKYLDSRRAQDFVQWLmNTKRNRNNIA-Ttds-EEEEEC-COOH |
156 | OXM174 | HαQGTFTSDYSKYLDSRRAC3DFVQWLANTKRNRNNIA-CONH2 |
157 | OXM175 | HαQGTFTSDYSKYLDSRRAC3DFVQWLVNTKRNRNNIA-CONH2 |
158 | OXM176 | HαQGTFTSDYSKYLDSRRAC3DFVQWLαNTKRNRNNIA-CONH2 |
159 | OXM199 | HαQGTFTSDYSKYLDSRRAC3DFVQWLXNTKRNRNNIA-CONH2 |
Claims (14)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77554406P | 2006-02-22 | 2006-02-22 | |
US60/775,544 | 2006-02-22 | ||
US83445206P | 2006-07-31 | 2006-07-31 | |
US60/834,452 | 2006-07-31 | ||
PCT/US2007/004306 WO2007100535A2 (en) | 2006-02-22 | 2007-02-16 | Oxyntomodulin derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101389648A true CN101389648A (zh) | 2009-03-18 |
CN101389648B CN101389648B (zh) | 2013-07-17 |
Family
ID=38309987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007800061855A Expired - Fee Related CN101389648B (zh) | 2006-02-22 | 2007-02-16 | 肽胃泌酸调节素衍生物 |
Country Status (7)
Country | Link |
---|---|
US (2) | US7928058B2 (zh) |
EP (3) | EP2471810A1 (zh) |
JP (1) | JP5297817B2 (zh) |
CN (1) | CN101389648B (zh) |
AU (1) | AU2007221366B2 (zh) |
CA (1) | CA2638800A1 (zh) |
WO (1) | WO2007100535A2 (zh) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102665752A (zh) * | 2009-12-22 | 2012-09-12 | 伊莱利利公司 | 泌酸调节肽类似物 |
CN103732616A (zh) * | 2011-06-17 | 2014-04-16 | 韩美科学株式会社 | 包括泌酸调节肽和免疫球蛋白片段的结合物以及其应用 |
CN103732618A (zh) * | 2011-06-10 | 2014-04-16 | 韩美科学株式会社 | 新型泌酸调节肽衍生物和包含该泌酸调节肽衍生物的用于治疗肥胖的药物组合物 |
CN104926934A (zh) * | 2014-09-23 | 2015-09-23 | 蒋先兴 | 胃泌酸调节素类似物 |
WO2016090628A1 (zh) * | 2014-12-12 | 2016-06-16 | 北京韩美药品有限公司 | 胃泌酸调节肽(oxm)类似物、其合成及应用 |
CN106046145A (zh) * | 2016-04-22 | 2016-10-26 | 深圳市图微安创科技开发有限公司 | Glp-1r/gcgr双靶点激动剂多肽治疗脂肪肝病、高脂血症和动脉硬化 |
CN106986924A (zh) * | 2017-03-23 | 2017-07-28 | 中国药科大学 | 胃泌酸调节素(oxm)类似物及其应用 |
US9724420B2 (en) | 2012-11-06 | 2017-08-08 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region |
US9901621B2 (en) | 2012-07-25 | 2018-02-27 | Hanmi Pharm. Co., Ltd. | Composition for treating hyperlipidemia comprising oxyntomodulin derivative |
CN109096387A (zh) * | 2012-06-04 | 2018-12-28 | 奥普科生物制品有限公司 | 聚乙二醇化的oxm变体 |
US10233230B2 (en) | 2014-09-16 | 2019-03-19 | Hanmi Pharm. Co., Ltd. | Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease |
WO2019085773A1 (zh) * | 2017-11-06 | 2019-05-09 | 中山大学 | 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗特发性肺间质纤维化 |
US10513550B2 (en) | 2014-12-30 | 2019-12-24 | Hanmi Pharm Co., Ltd | Glucagon derivatives |
US10550168B2 (en) | 2012-11-06 | 2020-02-04 | Hanmi Pharm. Co., Ltd. | Composition for treating diabetes or diabesity comprising oxyntomodulin analog |
WO2024032523A1 (zh) * | 2022-08-10 | 2024-02-15 | 成都奥达生物科技有限公司 | 一种长效双激动剂化合物 |
Families Citing this family (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU779986B2 (en) | 1999-06-29 | 2005-02-24 | Mannkind Corporation | Purification and stabilization of peptide and protein pharmaceutical agents |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
EP2050460A1 (en) | 2001-09-24 | 2009-04-22 | Imperial Innovations Limited | PYY and agonists thereof for modification of feeding behaviour |
ES2300568T3 (es) | 2002-03-20 | 2008-06-16 | Mannkind Corporation | Aparato de inhalacion. |
GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
MX2007001903A (es) | 2004-08-20 | 2007-08-02 | Mannkind Corp | Catalisis de sintesis de dicetopiperazina. |
KR101306384B1 (ko) | 2004-08-23 | 2013-09-09 | 맨카인드 코포레이션 | 약물 전달용 디케토피페라진염, 디케토모르포린염 또는디케토디옥산염 |
JP5465878B2 (ja) | 2005-09-14 | 2014-04-09 | マンカインド コーポレイション | 活性薬剤に対する結晶性微粒子表面の親和性を増大させることに基づく薬物処方の方法 |
WO2007056362A2 (en) | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
CN104383546B (zh) | 2006-02-22 | 2021-03-02 | 曼金德公司 | 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法 |
TWI428346B (zh) * | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
MX2009006564A (es) | 2007-01-05 | 2009-06-26 | Univ Indiana Res & Tech Corp | Analogos de glucagon que muestran solubilidad potenciada en amortiguadores a ph fisiologico. |
KR20090119876A (ko) | 2007-02-15 | 2009-11-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-항진물질 |
AU2008316636B2 (en) * | 2007-10-24 | 2014-02-06 | Mannkind Corporation | Delivery of active agents |
US8785396B2 (en) | 2007-10-24 | 2014-07-22 | Mannkind Corporation | Method and composition for treating migraines |
US8981047B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Glucagon antagonists |
ES2558155T3 (es) | 2007-10-30 | 2016-02-02 | Indiana University Research And Technology Corporation | Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1 |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
CN104689432B (zh) | 2008-06-13 | 2018-07-06 | 曼金德公司 | 干粉吸入器和用于药物输送的系统 |
WO2009155257A1 (en) | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers |
SG192405A1 (en) | 2008-06-17 | 2013-08-30 | Univ Indiana Res & Tech Corp | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
PA8830501A1 (es) | 2008-06-17 | 2010-07-27 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
JP5479465B2 (ja) | 2008-06-20 | 2014-04-23 | マンカインド コーポレイション | 吸入努力をリアルタイムにプロファイルする対話式機器および方法 |
CA2953975C (en) * | 2008-06-27 | 2019-11-26 | Duke University | Therapeutic agents comprising elastin-like peptides |
TWI494123B (zh) | 2008-08-11 | 2015-08-01 | Mannkind Corp | 超快起作用胰島素之用途 |
KR101581986B1 (ko) | 2008-10-29 | 2016-01-04 | 아블린쓰 엔.브이. | 단일 도메인 항원 결합 분자의 제형 |
CA2739352C (en) | 2008-10-29 | 2021-07-13 | Wyeth Llc | Methods for purification of single domain antigen binding molecules |
JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
PL2370460T3 (pl) | 2008-12-15 | 2014-09-30 | Zealand Pharma As | Analogi glukagonu |
CA2747155A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
CN102292348B (zh) | 2008-12-15 | 2015-07-08 | 西兰制药公司 | 胰高血糖素类似物 |
KR20110126589A (ko) | 2008-12-15 | 2011-11-23 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
JP2012512903A (ja) | 2008-12-19 | 2012-06-07 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | アミド系グルカゴンスーパーファミリーペプチドプロドラッグ |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
WO2010096052A1 (en) * | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
PL2405963T3 (pl) | 2009-03-11 | 2014-04-30 | Mannkind Corp | Urządzenie, układ i sposób pomiaru oporu inhalatora |
EP2440184B1 (en) | 2009-06-12 | 2023-04-05 | MannKind Corporation | Diketopiperazine microparticles with defined specific surface areas |
SG176858A1 (en) | 2009-06-16 | 2012-02-28 | Univ Indiana Res & Tech Corp | Gip receptor-active glucagon compounds |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
AP3329A (en) | 2009-07-13 | 2015-06-30 | Zealand Pharma As | Acylated glucagon analogues |
WO2011028455A1 (en) | 2009-09-02 | 2011-03-10 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
JO2976B1 (en) * | 2009-12-22 | 2016-03-15 | ايلي ليلي اند كومباني | Axentomodulin polypeptide |
CN102892425A (zh) | 2010-01-20 | 2013-01-23 | 西兰制药公司 | 心脏病症的治疗 |
EP2528618A4 (en) | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS |
WO2011103256A1 (en) | 2010-02-22 | 2011-08-25 | Merck Sharp & Dohme Corp. | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
CN103003300B (zh) | 2010-04-27 | 2017-06-09 | 西兰制药公司 | Glp‑1受体激动剂和胃泌素的肽缀合物及其用途 |
CA2797089A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
EP2569000B1 (en) | 2010-05-13 | 2017-09-27 | Indiana University Research and Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
EP2571876B1 (en) | 2010-05-21 | 2016-09-07 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
RU2571331C1 (ru) | 2010-06-21 | 2015-12-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
AP2013006671A0 (en) | 2010-06-24 | 2013-01-31 | Zealand Pharma As | Glucagon analogues |
MX2012014576A (es) | 2010-06-24 | 2013-02-21 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida. |
WO2012007880A2 (en) * | 2010-07-16 | 2012-01-19 | Ablynx Nv | Modified single domain antigen binding molecules and uses thereof |
MA34885B1 (fr) | 2010-12-22 | 2014-02-01 | Indiana Unversity Res And Technology Corp | Analogues du glucagon presentant una ctivite de recepteur de gip |
AU2012208349A1 (en) | 2011-01-20 | 2013-07-18 | Zealand Pharma A/S | Combination of acylated glucagon analogues with insulin analogues |
DK2694402T3 (en) | 2011-04-01 | 2017-07-03 | Mannkind Corp | BLISTER PACKAGE FOR PHARMACEUTICAL CYLINDER AMPULS |
WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
EP2707713A2 (en) | 2011-05-10 | 2014-03-19 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
CN104023739A (zh) | 2011-06-02 | 2014-09-03 | Opko生物科学有限公司 | 长效glp-1/胰高血糖素受体激动剂 |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
US9156902B2 (en) | 2011-06-22 | 2015-10-13 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
BR112013032717A2 (pt) | 2011-06-22 | 2017-01-24 | Univ Indiana Res & Tech Corp | coagonistas do receptor de glucagon/glp-1 |
KR20140070612A (ko) | 2011-09-23 | 2014-06-10 | 노보 노르디스크 에이/에스 | 신규 글루카곤 유사체 |
AU2012328885B2 (en) | 2011-10-24 | 2017-08-31 | Mannkind Corporation | Methods and compositions for treating pain |
MX2014005351A (es) | 2011-11-03 | 2014-05-28 | Zealand Pharma As | Conjugados de gastrina peptidicos de agonistas de receptor glp-1. |
CA2847246A1 (en) | 2011-11-17 | 2013-05-23 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
AP2014007797A0 (en) | 2011-12-23 | 2014-07-31 | Boehringer Ingelheim Int | Glucagon analogues |
WO2013155600A1 (en) | 2012-04-16 | 2013-10-24 | Kaneq Pharma | Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors |
MY167814A (en) | 2012-04-19 | 2018-09-26 | Opko Biologics Ltd | Long-acting oxyntomodulin variants and methods of producing same |
AR090937A1 (es) | 2012-05-03 | 2014-12-17 | Zealand Pharma As | Compuestos agonista duales de gip-glp-1 y metodos para usarlos |
CA2877358A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
AU2013289957B2 (en) | 2012-07-12 | 2017-02-23 | Mannkind Corporation | Dry powder drug delivery systems and methods |
CN109456400A (zh) | 2012-07-23 | 2019-03-12 | 西兰制药公司 | 胰高血糖素类似物 |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
WO2014049610A2 (en) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
CA2891393A1 (en) | 2012-11-20 | 2014-05-30 | Opko Biologics Ltd. | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides |
EP3587404B1 (en) | 2013-03-15 | 2022-07-13 | MannKind Corporation | Microcrystalline diketopiperazine compositions, methods for preparation and use thereof |
WO2014170496A1 (en) | 2013-04-18 | 2014-10-23 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
BR112016000937A8 (pt) | 2013-07-18 | 2021-06-22 | Mannkind Corp | formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco |
JP2016530930A (ja) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | 通気装置及び方法 |
PT3057984T (pt) | 2013-10-17 | 2018-10-24 | Boehringer Ingelheim Int | Análogos de glucagon acilados |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
CN105849122B (zh) | 2013-11-06 | 2021-04-30 | 西兰制药公司 | Gip-glp-1双重激动剂化合物及方法 |
CA2929107C (en) | 2013-11-06 | 2023-09-26 | Zealand Pharma A/S | Glucagon-glp-1-gip triple agonist compounds |
WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
JP6018129B2 (ja) * | 2014-07-04 | 2016-11-02 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
JP5912150B2 (ja) * | 2014-07-04 | 2016-04-27 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
JP5912151B2 (ja) * | 2014-07-04 | 2016-04-27 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
JP6006264B2 (ja) * | 2014-07-16 | 2016-10-12 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
EP3985016A1 (en) | 2014-10-29 | 2022-04-20 | Zealand Pharma A/S | Gip agonist compounds and methods |
WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
US10336802B2 (en) | 2015-04-16 | 2019-07-02 | Zealand Pharma A/S | Acylated glucagon analogue |
EP3302571B1 (en) * | 2015-05-29 | 2020-11-18 | OPKO Biologics Ltd. | Pegylated oxyntomodulin variants |
CN108289851B (zh) | 2015-06-19 | 2021-06-01 | Opko生物科学有限公司 | 长效凝固因子及其产生方法 |
CN108602894A (zh) * | 2015-10-30 | 2018-09-28 | 纽约州立大学研究基金会 | 胃泌酸调节素类似物及其制备和使用方法 |
EP3394091A4 (en) | 2015-12-09 | 2019-12-18 | Merck Sharp & Dohme Corp. | CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS |
WO2017212494A1 (en) | 2016-06-09 | 2017-12-14 | Opko Biologics Ltd. | Long-acting oxyntomodulin formulation and methods of producing and administering same |
BR112019010624A2 (pt) | 2016-12-09 | 2019-10-22 | Zealand Pharma As | agonistas duplos de glp-1/glp-2 acilados e composição |
CN111094331B (zh) * | 2017-08-16 | 2024-03-29 | 东亚St株式会社 | 酰化胃泌酸调节素肽类似物 |
WO2020017919A1 (ko) * | 2018-07-19 | 2020-01-23 | 한미정밀화학주식회사 | 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법 |
US20220242913A1 (en) * | 2019-02-15 | 2022-08-04 | Hanmi Fine Chemical Co., Ltd. | Novel intermediate used for biologically active polypeptide and method for preparing same |
EP4331600A1 (en) * | 2021-04-30 | 2024-03-06 | Innovent Biologics (Suzhou) Co., Ltd. | Oxm3 storage agent, oxm3 preparation, and preparation method |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060014254A1 (en) * | 2003-01-22 | 2006-01-19 | Human Genome Sciences, Inc. | Albumin fusion proteins |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US6271011B1 (en) * | 1996-10-15 | 2001-08-07 | The University Of Georgia Research Foundation, Inc. | Pasteurella neuraminidase coding sequences and diagnostic methods |
US6692923B2 (en) * | 1999-04-14 | 2004-02-17 | Incyte Corporation | Tapasin-like protein |
US6677136B2 (en) * | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
KR20040054729A (ko) * | 2001-10-18 | 2004-06-25 | 브리스톨-마이어스 스큅 컴퍼니 | 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도 |
CA2478183C (en) | 2002-03-12 | 2010-02-16 | Merck & Co. Inc. | Substituted amides |
GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
RU2006100298A (ru) | 2003-06-11 | 2006-05-10 | Мерк энд Ко., Инк. (US) | Замещенные производные 3-алкил-и 3-алкенилазетидинов |
WO2005066207A1 (en) * | 2004-01-08 | 2005-07-21 | Theratechnologies Inc. | Glucagon-like peptide-1 analogs with long duration of action |
WO2005077072A2 (en) * | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
TW200611704A (en) * | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
CN101128487B (zh) * | 2004-12-02 | 2012-10-10 | 杜门蒂斯有限公司 | 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体 |
WO2007022123A2 (en) * | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
EP2390264A1 (en) * | 2005-02-11 | 2011-11-30 | Amylin Pharmaceuticals Inc. | GIP analog and hybrid polypeptides with selectable propperties |
WO2006134340A2 (en) * | 2005-06-13 | 2006-12-21 | Imperial Innovations Limited | Oxyntomodulin analogues and their effects on feeding behaviour |
WO2007056362A2 (en) * | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
-
2007
- 2007-02-16 US US12/223,942 patent/US7928058B2/en active Active
- 2007-02-16 EP EP12159697A patent/EP2471810A1/en not_active Withdrawn
- 2007-02-16 EP EP07751091.5A patent/EP1991574B1/en active Active
- 2007-02-16 CN CN2007800061855A patent/CN101389648B/zh not_active Expired - Fee Related
- 2007-02-16 EP EP12159705.8A patent/EP2471811B1/en active Active
- 2007-02-16 CA CA002638800A patent/CA2638800A1/en not_active Abandoned
- 2007-02-16 WO PCT/US2007/004306 patent/WO2007100535A2/en active Application Filing
- 2007-02-16 AU AU2007221366A patent/AU2007221366B2/en not_active Ceased
- 2007-02-16 JP JP2008556379A patent/JP5297817B2/ja not_active Expired - Fee Related
-
2011
- 2011-03-21 US US13/052,270 patent/US8268779B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060014254A1 (en) * | 2003-01-22 | 2006-01-19 | Human Genome Sciences, Inc. | Albumin fusion proteins |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102665752B (zh) * | 2009-12-22 | 2015-01-21 | 伊莱利利公司 | 泌酸调节肽类似物 |
CN102665752A (zh) * | 2009-12-22 | 2012-09-12 | 伊莱利利公司 | 泌酸调节肽类似物 |
US9527898B2 (en) | 2011-06-10 | 2016-12-27 | Hanmi Science Co., Ltd. | Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
CN103732618A (zh) * | 2011-06-10 | 2014-04-16 | 韩美科学株式会社 | 新型泌酸调节肽衍生物和包含该泌酸调节肽衍生物的用于治疗肥胖的药物组合物 |
US10442848B2 (en) | 2011-06-10 | 2019-10-15 | Hanmi Science Co., Ltd. | Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
US9522946B2 (en) | 2011-06-10 | 2016-12-20 | Hanmi Science Co., Ltd. | Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
US9765131B2 (en) | 2011-06-10 | 2017-09-19 | Hanmi Science Co., Ltd. | Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
CN103732618B (zh) * | 2011-06-10 | 2018-10-09 | 韩美科学株式会社 | 新型泌酸调节肽衍生物和包含该泌酸调节肽衍生物的用于治疗肥胖的药物组合物 |
US11872283B2 (en) | 2011-06-17 | 2024-01-16 | Hanmi Science Co., Ltd | Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
US10363320B2 (en) | 2011-06-17 | 2019-07-30 | Hanmi Science Co., Ltd. | Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
CN109306015A (zh) * | 2011-06-17 | 2019-02-05 | 韩美科学株式会社 | 包括泌酸调节肽和免疫球蛋白片段的结合物以及其应用 |
CN103732616A (zh) * | 2011-06-17 | 2014-04-16 | 韩美科学株式会社 | 包括泌酸调节肽和免疫球蛋白片段的结合物以及其应用 |
CN103732616B (zh) * | 2011-06-17 | 2018-08-17 | 韩美科学株式会社 | 包括泌酸调节肽和免疫球蛋白片段的结合物以及其应用 |
US9731031B2 (en) | 2011-06-17 | 2017-08-15 | Hanmi Science Co., Ltd. | Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
CN109096387A (zh) * | 2012-06-04 | 2018-12-28 | 奥普科生物制品有限公司 | 聚乙二醇化的oxm变体 |
CN109096387B (zh) * | 2012-06-04 | 2021-11-30 | 奥普科生物制品有限公司 | 聚乙二醇化的oxm变体 |
US10493132B2 (en) | 2012-07-25 | 2019-12-03 | Hanmi Pharm. Co., Ltd. | Composition for treating hyperlipidemia comprising oxyntomodulin derivative |
US9901621B2 (en) | 2012-07-25 | 2018-02-27 | Hanmi Pharm. Co., Ltd. | Composition for treating hyperlipidemia comprising oxyntomodulin derivative |
US9724420B2 (en) | 2012-11-06 | 2017-08-08 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region |
US11071785B2 (en) | 2012-11-06 | 2021-07-27 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long-lasting protein conjugate comprising the oxyntomodulin and an immunoglobulin Fc region |
US10550168B2 (en) | 2012-11-06 | 2020-02-04 | Hanmi Pharm. Co., Ltd. | Composition for treating diabetes or diabesity comprising oxyntomodulin analog |
US10279041B2 (en) | 2012-11-06 | 2019-05-07 | Hanmi Pharm Co. Ltd. | Liquid formulation of long-lasting protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
US10435459B2 (en) | 2014-09-16 | 2019-10-08 | Hanmi Pharm. Co., Ltd. | Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease |
US10233230B2 (en) | 2014-09-16 | 2019-03-19 | Hanmi Pharm. Co., Ltd. | Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease |
WO2016045400A1 (zh) * | 2014-09-23 | 2016-03-31 | 蒋先兴 | 胃泌酸调节素类似物 |
CN106519015B (zh) * | 2014-09-23 | 2020-04-17 | 深圳市图微安创科技开发有限公司 | 胃泌酸调节素类似物 |
US10479819B2 (en) | 2014-09-23 | 2019-11-19 | Xianxing JIANG | Oxyntomodulin analogue |
CN104926934A (zh) * | 2014-09-23 | 2015-09-23 | 蒋先兴 | 胃泌酸调节素类似物 |
CN106519015A (zh) * | 2014-09-23 | 2017-03-22 | 蒋先兴 | 胃泌酸调节素类似物 |
WO2016090628A1 (zh) * | 2014-12-12 | 2016-06-16 | 北京韩美药品有限公司 | 胃泌酸调节肽(oxm)类似物、其合成及应用 |
US10513550B2 (en) | 2014-12-30 | 2019-12-24 | Hanmi Pharm Co., Ltd | Glucagon derivatives |
US11254724B2 (en) | 2014-12-30 | 2022-02-22 | Hanmi Pharm. Co., Ltd. | Glucagon derivatives |
CN106046145A (zh) * | 2016-04-22 | 2016-10-26 | 深圳市图微安创科技开发有限公司 | Glp-1r/gcgr双靶点激动剂多肽治疗脂肪肝病、高脂血症和动脉硬化 |
US11197914B2 (en) | 2016-04-22 | 2021-12-14 | Shenzhen Turier Biotech Co. Ltd. | GLP-1R/GCGR dual target agonist polypeptide for treatment of fatty liver diseases, hyperlipemia and arteriosclerosis |
CN106046145B (zh) * | 2016-04-22 | 2022-11-04 | 深圳市图微安创科技开发有限公司 | Glp-1r/gcgr双靶点激动剂多肽治疗脂肪肝病、高脂血症和动脉硬化 |
CN106986924A (zh) * | 2017-03-23 | 2017-07-28 | 中国药科大学 | 胃泌酸调节素(oxm)类似物及其应用 |
WO2019085773A1 (zh) * | 2017-11-06 | 2019-05-09 | 中山大学 | 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗特发性肺间质纤维化 |
WO2024032523A1 (zh) * | 2022-08-10 | 2024-02-15 | 成都奥达生物科技有限公司 | 一种长效双激动剂化合物 |
Also Published As
Publication number | Publication date |
---|---|
US20110183902A1 (en) | 2011-07-28 |
JP5297817B2 (ja) | 2013-09-25 |
EP1991574A2 (en) | 2008-11-19 |
US8268779B2 (en) | 2012-09-18 |
WO2007100535A2 (en) | 2007-09-07 |
EP1991574B1 (en) | 2016-10-12 |
US7928058B2 (en) | 2011-04-19 |
CA2638800A1 (en) | 2007-09-07 |
EP2471811A1 (en) | 2012-07-04 |
EP2471810A1 (en) | 2012-07-04 |
EP2471811B1 (en) | 2015-09-16 |
EP2471811A9 (en) | 2013-10-09 |
AU2007221366B2 (en) | 2012-08-23 |
WO2007100535A3 (en) | 2008-03-20 |
CN101389648B (zh) | 2013-07-17 |
AU2007221366A1 (en) | 2007-09-07 |
US20100144617A1 (en) | 2010-06-10 |
JP2009527558A (ja) | 2009-07-30 |
AU2007221366A8 (en) | 2012-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101389648B (zh) | 肽胃泌酸调节素衍生物 | |
JP7386218B2 (ja) | グルカゴン及びglp-1共アゴニスト化合物 | |
JP6412183B2 (ja) | 作用持続時間が増した改変ポリペプチド | |
CN103596972B (zh) | 多肽 | |
JP4282485B2 (ja) | 伸長グルカゴン様ペプチド−1アナログ | |
JP5703226B2 (ja) | アミリン誘導体 | |
US20100267610A1 (en) | Polypeptide comprising a knottin protein moiety | |
TW201427993A (zh) | 用於治療肥胖之升糖素與glp-1共促效劑 | |
JP2010539132A (ja) | アミリンの改良された誘導体 | |
WO2003103572A2 (en) | Modified glucagon-like peptide-1 analogs | |
AU2003200839A2 (en) | Extended glucagon-like peptide-1 analogs | |
US20180161443A1 (en) | Growth hormone polypeptides and methods of making and using same | |
MX2013004350A (es) | Analogos de peptido insulinotropico dependientes de glucosa. | |
Kanematsu-Yamaki et al. | Potent body weight-lowering effect of a neuromedin U receptor 2-selective PEGylated peptide | |
CN106554404A (zh) | 一种艾塞那肽修饰物及其用途 | |
Niida et al. | Antiobesity and emetic effects of a short-length peptide YY analog and its PEGylated and alkylated derivatives | |
CN115960258B (zh) | 一类GLP-1/glucagon/Y2受体三重激动剂及其应用 | |
CN115819619A (zh) | 一类glp-1/y2受体双重激动剂及其应用 | |
US20090042802A1 (en) | Compounds and peptides that bind the kgf receptor | |
CN115873096A (zh) | 一种胰高血糖素糖肽-1和胰高血糖素受体双重激动多肽及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SCHERING CORP (US) Free format text: FORMER OWNER: MSD CORP. Effective date: 20121109 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: New jersey, USA Applicant after: MERCK SHARP & DOHME Corp. Applicant after: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. Address before: New jersey, USA Applicant before: SCHERING Corp. Applicant before: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SCHERING CORP (US) TO: MSD CORP. |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20121109 Address after: New jersey, USA Applicant after: SCHERING Corp. Applicant after: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. Address before: New jersey, USA Applicant before: MERCK SHARP & DOHME Corp. Applicant before: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: MSD ITALY S. P. A. Free format text: FORMER OWNER: ANGELETTI P. IST RICHERCHE BIO. Effective date: 20140624 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140624 Address after: New jersey, USA Patentee after: MERCK SHARP & DOHME Corp. Patentee after: MSD Italia S.R.L. Address before: New jersey, USA Patentee before: MERCK SHARP & DOHME Corp. Patentee before: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130717 Termination date: 20160216 |